For those in the semaglutide group, the weight-loss trajectory continued to week 65 and then was sustained for the study period through week 208 (10.2% for the semaglutide group, 1.5% for the placebo group
Muyyarikkandy MS, McLeod M, Maguire M, Mahar R, Kattapuram N, Zhang C, Surugihalli C, Muralidaran V, Vavilikolanu K, Mathews CE, Merritt ME, Sunny NE
MiR-146a regulates regulatory T cells to suppress heart transplant rejection in mice
How Lipo B and Tirzepatide Work Through Different Pathways Tirzepatide activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors with high affinity
Clinical systems capture intervention
Among those with preexisting SUDs, GLP-1s were linked to lower risks of emergency room visits, hospitalizations, mortality, overdose, and suicidal thoughts or attempts